Évaluation en TEP 18F-FDG de la réponse au traitement par CAR T-Cells et anticorps bispécifiques des lymphomes non hodgkiniens agressifs

Refractory or relapsing aggressive non-Hodgkin lymphomas have improved prognosis in the last few years thanks to innovative therapies such as CAR T-cells and bispecific antibodies. During these therapeutic strategies, tumoral response assessment with FDG PET remains of paramount importance. However, due to their mode of action, these treatments can result in delayed responses or in inflammatory events that may hamper interpretation of metabolic imaging. Lugano criteria, relying on the Deauville score, are useful, but it is crucial to be aware of the interpretation pitfalls and to consider all the clinical and biological background of the patient, ideally in a multidisciplinary approach.